Swarm Oncology to present at Bio€quity Europe 2025

London, U.K., May 8 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “the Company”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today announces that it will be presenting at the 25^th annual Bio€quity Europe 2025 Conference, taking place from 12-14 May 2025, in Bruges, Belgium.

Martin Olin, Chief Executive Officer at Swarm Oncology will deliver the presentation on Novel Immunotherapy for Solid Cancers.

Details of presentation:

Title: Novel Immunotherapy for Solid Cancers
Presenter: Martin Olin
Session: Cancer Track
Session date and time: 14 May 2025, 12:00pm BST / 1:00pm CEST
Session location: Room 4&5 Bruges Meeting & Convention Centre

If you would like to arrange a meeting at the conference, please contact: [email protected]    

About Swarm Oncology

Swarm Oncology is developing novel potent T cell therapies which are designed to overcome major shortcomings of immunotherapy approaches with the goal to drive solid cancers to complete remission.

For further information, contact:

Swarm Oncology
[email protected]    

ICR Healthcare
Mary-Jane Elliott, Davide Salvi, Emily Johnson
[email protected]

You May Also Be Interested In

• Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• EnerPure Closes US$35 Million Commercialization Financing
• Prospect Capital Announces June 2026 Results